Q1 2021

Filed May 17, 2021 · 10-Q · 47 days after period end · 0001654954-21-005897

Q1 2021 · 10-Q

Revenue

$0.00

— vs Q1 2020

Net Income

-$29.68M

N/M vs Q1 2020

EPS Diluted

-$1.83

N/M vs Q1 2020

Operating Income-$29,002,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2021	Q1 2020	Q1 2019	Q1 2018
Revenue	$0.00	$0.00	$0.00	$0.00
Net Income	-$29.68M	-$1.71M	-$4.51M	-$10.09M
EPS Diluted	-$1.83	-$0.02	-$0.09	-$0.20

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR